Sangamo Therapeutics, Inc. - stock earnings
SGMO Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 AfterMarket | - / -0.2180000000 | - | - / 6.8 million | - |
SGMO Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -60.3 million USD | 2.0 million USD |
| 2023Q3 | -104.2 million USD | 9.4 million USD |
| 2023Q2 | -114.5 million USD | 6.8 million USD |
| 2023Q1 | 21.1 million USD | 158.0 million USD |
| 2022Q4 | -52.0 million USD | 27.2 million USD |
| 2022Q3 | -53.2 million USD | 26.5 million USD |
| 2022Q2 | -43.2 million USD | 29.4 million USD |
| 2022Q1 | -44.0 million USD | 28.2 million USD |
| 2021Q4 | -37.5 million USD | 28.0 million USD |
| 2021Q3 | -47.7 million USD | 28.6 million USD |
| 2021Q2 | -47.2 million USD | 27.9 million USD |
| 2021Q1 | -45.9 million USD | 26.3 million USD |
| 2020Q4 | -40.6 million USD | 25.8 million USD |
| 2020Q3 | -1.6 million USD | 57.8 million USD |
| 2020Q2 | -35.9 million USD | 21.6 million USD |
| 2020Q1 | -42.9 million USD | 13.1 million USD |
| 2019Q4 | 4.6 million USD | 54.9 million USD |
| 2019Q3 | -27.3 million USD | 22.0 million USD |
| 2019Q2 | -30.3 million USD | 17.5 million USD |
| 2019Q1 | -42.2 million USD | 8.1 million USD |
| 2018Q4 | -18.7 million USD | 26.8 million USD |
| 2018Q3 | -12.8 million USD | 23.6 million USD |
| 2018Q2 | -16.6 million USD | 21.4 million USD |
| 2018Q1 | -20.2 million USD | 12.6 million USD |
| 2017Q4 | -13.1 million USD | 13.1 million USD |
| 2017Q3 | -12.4 million USD | 11.8 million USD |
| 2017Q2 | -12.5 million USD | 8.3 million USD |
| 2017Q1 | -16.6 million USD | 3.4 million USD |
| 2016Q4 | -9.6 million USD | 8.9 million USD |
| 2016Q3 | -19.0 million USD | 2.8 million USD |
| 2016Q2 | -26.6 million USD | 3.7 million USD |
| 2016Q1 | -16.5 million USD | 3.9 million USD |
| 2015Q4 | -14.0 million USD | 9.1 million USD |
| 2015Q3 | -9.2 million USD | 8.6 million USD |
| 2015Q2 | -12.1 million USD | 8.4 million USD |
| 2015Q1 | -5.3 million USD | 13.5 million USD |
| 2014Q4 | -4.3 million USD | 15.0 million USD |
| 2014Q3 | -7.5 million USD | 12.4 million USD |
| 2014Q2 | -7.0 million USD | 10.4 million USD |
| 2014Q1 | -7.6 million USD | 8.1 million USD |
| 2013Q4 | -8.1 million USD | 6.9 million USD |
| 2013Q3 | -6.1 million USD | 5.7 million USD |
| 2013Q2 | -5.5 million USD | 6.9 million USD |
| 2013Q1 | -6.9 million USD | 4.6 million USD |
| 2012Q4 | -3.5 million USD | 8.9 million USD |
| 2012Q3 | -5.8 million USD | 4.9 million USD |
| 2012Q2 | -5.7 million USD | 4.6 million USD |
| 2012Q1 | -7.3 million USD | 3.2 million USD |
| 2011Q4 | -6.4 million USD | 4.7 million USD |
| 2011Q3 | -9.6 million USD | 1.9 million USD |
| 2011Q2 | -10.3 million USD | 1.5 million USD |
| 2011Q1 | -9.6 million USD | 2.2 million USD |
| 2010Q4 | -8.3 million USD | 4.7 million USD |
| 2010Q3 | -8.7 million USD | 2.9 million USD |
| 2010Q2 | -3.9 million USD | 6.5 million USD |
| 2010Q1 | -4.0 million USD | 6.6 million USD |
| 2009Q4 | -2.4 million USD | 10.2 million USD |
| 2009Q3 | -4.9 million USD | 4.1 million USD |
| 2009Q2 | -4.5 million USD | 4.7 million USD |
| 2009Q1 | -6.8 million USD | 3.2 million USD |
| 2008Q4 | -2.6 million USD | 6.8 million USD |
| 2008Q3 | -6.3 million USD | 3.7 million USD |
| 2008Q2 | -7.4 million USD | 2.8 million USD |
| 2008Q1 | -8.0 million USD | 2.8 million USD |
| 2007Q4 | -6.7 million USD | 2.8 million USD |
| 2007Q3 | -4.3 million USD | 2.3 million USD |
| 2007Q2 | -5.2 million USD | 2.6 million USD |
| 2007Q1 | -5.4 million USD | 1.4 million USD |
| 2006Q4 | -8.9 million USD | 2.2 million USD |
| 2006Q3 | -2.8 million USD | 1.8 million USD |
| 2006Q2 | -3.3 million USD | 1.8 million USD |
| 2006Q1 | -2.7 million USD | 2.1 million USD |
| 2005Q4 | -2.7 million USD | 1.4 million USD |
| 2005Q3 | -3.7 million USD | 412000 USD |
| 2005Q2 | -3.4 million USD | 418000 USD |
| 2005Q1 | -3.6 million USD | 256000 USD |
| 2004Q4 | -3.0 million USD | 200000 USD |
| 2004Q3 | -4.6 million USD | 172000 USD |
| 2004Q2 | -3.3 million USD | 132000 USD |
| 2004Q1 | -2.9 million USD | 811000 USD |
| 2003Q4 | -1.7 million USD | 1.0 million USD |
| 2003Q3 | -2.6 million USD | 507000 USD |
| 2003Q2 | -3.3 million USD | 518000 USD |
| 2003Q1 | -2.9 million USD | 551000 USD |
| 2002Q4 | -706000 USD | 2.5 million USD |
| 2002Q3 | -20.9 million USD | 1.0 million USD |
| 2002Q2 | -3.6 million USD | 366000 USD |
| 2002Q1 | -4.5 million USD | 501000 USD |
| 2001Q4 | -3.4 million USD | 2.2 million USD |
| 2001Q3 | -17.4 million USD | 739000 USD |
| 2001Q2 | -2.4 million USD | 1.3 million USD |
| 2001Q1 | -2.1 million USD | 634000 USD |
| 2000Q4 | -2.8 million USD | 1.1 million USD |
| 2000Q3 | -1.8 million USD | 823000 USD |
| 2000Q2 | -1.7 million USD | 747000 USD |
| 2000Q1 | -2.7 million USD | 807000 USD |
SGMO Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -257.8 million USD | 176.2 million USD |
| 2022 | -192.3 million USD | 111.3 million USD |
| 2021 | -178.3 million USD | 110.7 million USD |
| 2020 | -121.1 million USD | 118.2 million USD |
| 2019 | -75.8 million USD | 102.4 million USD |
| 2018 | -68.3 million USD | 84.5 million USD |
| 2017 | -54.6 million USD | 36.6 million USD |
| 2016 | -71.7 million USD | 19.4 million USD |
| 2015 | -40.7 million USD | 39.5 million USD |
| 2014 | -26.4 million USD | 45.9 million USD |
| 2013 | -26.6 million USD | 24.1 million USD |
| 2012 | -22.3 million USD | 21.7 million USD |
| 2011 | -35.8 million USD | 10.3 million USD |
| 2010 | -24.9 million USD | 20.8 million USD |
| 2009 | -18.6 million USD | 22.2 million USD |
| 2008 | -24.3 million USD | 16.2 million USD |
| 2007 | -21.5 million USD | 9.1 million USD |
| 2006 | -17.9 million USD | 7.9 million USD |
| 2005 | -13.3 million USD | 2.5 million USD |
| 2004 | -13.8 million USD | 1.3 million USD |
| 2003 | -10.4 million USD | 2.6 million USD |
| 2002 | -29.8 million USD | 4.3 million USD |
| 2001 | -25.2 million USD | 4.9 million USD |
| 2000 | -9.1 million USD | 3.4 million USD |
| 1999 | -3.8 million USD | 2.2 million USD |
| 1998 | -3.3 million USD | 2.0 million USD |
| 1997 | -1.4 million USD | 1.2 million USD |
| 1996 | -308000 USD | 632000 USD |
SGMO
Price: $0.56
52 week price:
Earnings Per Share: -1.48 USD
P/E Ratio: -0.39
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 882100
Ebitda: -12.6 millionMarket Capitalization: 115.3 million